Rios Casas Francisco, Armitage Jacob, Yuan Joanna, Liu Shan, Mokdad Ali H
Population Health Initiative, Hans Rosling Center for Population Health, University of Washington, Box 351622, 3980 15th Ave NE, Seattle, WA, 98195, USA.
Department of Industrial & Systems Engineering University of Washington, Box 352650, Seattle, WA, 98195, USA.
Heliyon. 2024 Jul 19;10(14):e34906. doi: 10.1016/j.heliyon.2024.e34906. eCollection 2024 Jul 30.
Numerous social and behavioral factors have been implicated in vaccination coverage. There is no single measure that describes a country's ability to improve or maintain its immunization coverage.
We estimated the "Vaccination Improvement Potential" (VIP) by taking the geometric mean of 13 different indicators on health financing, vaccine confidence, and socio-demographics for more than 200 countries across 30 years. Potential VIP Index values range from 0 to 1, with a higher score indicating greater potential to improve or maintain high vaccination rates.
In 1990, the mean VIP score was 0.49 (range = 0.13 to 0.86). In 2019, the mean score was 0.59 (range = 0.25 to 0.84). Consistent high performers included countries in Western Europe and high-income North America and East Asia. Important differences in subcomponents of the index drove major trends including vaccine hesitancy in Western Europe and Asia as well as lower levels of per capita health spending and development assistance in sub-Saharan Africa.
The VIP Index is a first-of-its-kind tool for understanding the capacity that exists in a country to realize improved immunization rates. It is a new resource that can guide researchers, policymakers, and health officials to more effectively deploy resources to realize improvements in vaccination coverage, assess the impact of those improvements, and identify countries that might require additional support to improve vaccine coverage.
Merck Sharp & Dohme Corp.
许多社会和行为因素与疫苗接种覆盖率有关。没有单一的衡量标准能够描述一个国家提高或维持其免疫接种覆盖率的能力。
我们通过对200多个国家30年间健康融资、疫苗信心和社会人口统计学等13项不同指标的几何平均值来估算“疫苗接种改善潜力”（VIP）。潜在的VIP指数值范围为0至1，分数越高表明提高或维持高疫苗接种率的潜力越大。
1990年，VIP平均得分为0.49（范围=0.13至0.86）。2019年，平均得分为0.59（范围=0.25至0.84）。表现持续优异的国家包括西欧、高收入的北美和东亚的国家。该指数各子成分的重要差异推动了主要趋势，包括西欧和亚洲的疫苗犹豫现象，以及撒哈拉以南非洲较低的人均卫生支出和发展援助水平。
VIP指数是了解一个国家实现提高免疫接种率能力的首创工具。它是一种新资源，可指导研究人员、政策制定者和卫生官员更有效地调配资源，以提高疫苗接种覆盖率，评估这些改进的影响，并确定可能需要额外支持以提高疫苗覆盖率的国家。
默克雪兰诺公司
